Biomarker panels for improved risk prediction and enhanced biological insights in patients with atrial fibrillation

Pascal B. Meyre,Stefanie Aeschbacher,Steffen Blum,Tobias Reichlin,Moa Haller,Nicolas Rodondi,Andreas S. Mueller,Alain Bernheim,Hans Huerg Beer,Giorgio Moschovitis,Andre Ziegler,Bianca Wahrenberger,Elia Rigamonti,Giulio Conte,Philipp Krisai,Leo H. Bonati,Stefan Osswald,Michael Kuehne,David Conen
DOI: https://doi.org/10.1101/2024.12.19.24319346
2024-12-24
Abstract:Atrial fibrillation (AF) is associated with an increased risk of adverse cardiovascular events, but the underlying biological mechanisms remain incompletely understood. Here we evaluated a panel of 12 circulating biomarkers representing diverse pathophysiological pathways in a cohort of 3,817 AF patients to assess their association with adverse cardiovascular outcomes. We identified 5 biomarkers - d-dimer, growth differentiation factor 15 (GDF-15), interleukin-6 (IL-6), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin T (hsTropT) - that were independently associated with cardiovascular death, stroke, myocardial infarction, and systemic embolism, significantly enhancing predictive accuracy. Additionally, GDF-15, insulin-like growth factor-binding protein-7 (IGFBP-7), NT-proBNP, and hsTropT were strong predictors of heart failure hospitalization, while GDF-15 and IL-6 were associated with major bleeding events. Incorporating IL-6, NT-proBNP, and hsTropT to the CHA₂DS₂-VASc score improved stroke risk prediction. Machine learning models incorporating these biomarkers demonstrated consistent improvements in risk stratification across all outcomes. Our results highlight the potential of integrating biomarkers related to myocardial injury, inflammation, oxidative stress, and coagulation into both conventional and machine learning-based models refine prognosis and guide clinical decision-making in AF patients.
What problem does this paper attempt to address?